Trump Medical Marijuana Reclassification — Federal Policy Changes Explained

Executive Summary

The Trump administration announced in May 2026 a policy to reclassify state-licensed medical marijuana under federal law, marking the most significant shift in federal cannabis policy since the Controlled Substances Act of 1970. The reclassification does not remove marijuana from Schedule I of the Controlled Substances Act, but instead creates a new regulatory pathway for state-licensed medical cannabis programs to operate without federal prosecution. The policy affects approximately 38 states with active medical marijuana programs, covering an estimated 7.2 million registered patients and a $15 billion annual market. Under the new framework, state-licensed medical dispensaries and cultivators must register with the Drug Enforcement Administration and comply with federal tracking requirements, but will no longer face asset forfeiture or criminal prosecution under 21 U.S.C. § 841. The policy does not address recreational cannabis, does not resolve Internal Revenue Code Section 280E tax penalties, and does not permit interstate commerce. Implementation began June 1, 2026, with a 180-day registration window for existing state-licensed operators.

Why This Matters

This reclassification represents the first time the federal government has formally recognized state medical marijuana programs as legitimate under federal law. The policy affects multiple stakeholder groups across the cannabis ecosystem. For patients, the change reduces fear of federal prosecution and may expand access as more physicians feel comfortable recommending medical cannabis without risking DEA license revocation. An estimated 7.2 million registered medical marijuana patients across 38 states stand to benefit from increased program stability.

For operators, the reclassification provides critical legal certainty. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings collectively operate over 600 medical dispensaries that previously existed in legal limbo. The policy enables these companies to pursue previously unavailable banking relationships, as financial institutions no longer face Bank Secrecy Act violations for serving registered medical cannabis businesses.

The economic scale is substantial. The medical marijuana market generated $14.8 billion in sales in 2025, according to BDSA Analytics. State tax revenues from medical programs totaled $1.9 billion in 2025. However, operators still face Section 280E tax burdens, which prevent deduction of ordinary business expenses and result in effective tax rates exceeding 70 percent for many cannabis companies.

For state governments, the policy validates years of regulatory infrastructure development. States including California, Colorado, Arizona, and Florida have invested hundreds of millions in seed-to-sale tracking systems, laboratory testing requirements, and licensing frameworks. The federal reclassification does not preempt state law, but creates a complementary federal registration system.

Background and History

The path to federal reclassification of medical marijuana spans five decades of policy conflict between state and federal governments.

The Controlled Substances Act (1970)

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., established the five-schedule classification system for drugs. Congress placed marijuana in Schedule I, defined as substances with high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. Schedule I includes heroin, LSD, and peyote. The classification made marijuana possession, cultivation, and distribution federal crimes under 21 U.S.C. § 841, carrying penalties up to life imprisonment for large-scale trafficking.

California Proposition 215 (1996)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, by a margin of 56 percent to 44 percent. The initiative allowed patients with a physician's recommendation to possess and cultivate marijuana for medical purposes. The law created direct conflict with federal law but relied on principles of federalism and state sovereignty. Twelve other states passed medical marijuana laws between 1998 and 2004, including Oregon, Washington, Alaska, Maine, and Nevada.

Gonzales v. Raich (2005)

The Supreme Court ruled 6-3 in Gonzales v. Raich, 545 U.S. 1 (2005), that the federal government could prosecute medical marijuana patients even in states with legal programs. The Court held that the Commerce Clause granted Congress authority to regulate marijuana as part of a comprehensive scheme to control interstate drug markets. Justice Stevens wrote for the majority that homegrown marijuana for medical use substantially affected interstate commerce. The decision affirmed federal supremacy but did not require states to criminalize medical marijuana.

Ogden Memo (2009)

Deputy Attorney General David Ogden issued a memorandum on October 19, 2009, directing federal prosecutors not to prioritize enforcement against individuals in clear compliance with state medical marijuana laws. The memo stated that prosecuting patients with serious illnesses or their caregivers was not an efficient use of limited federal resources. The policy applied only to medical marijuana and explicitly excluded commercial cultivation and distribution. The memo did not change federal law but created de facto tolerance for state programs.

Cole Memo (2013)

Deputy Attorney General James Cole issued updated guidance on August 29, 2013, following Colorado and Washington voter approval of recreational marijuana in 2012. The Cole Memo outlined eight federal enforcement priorities, including preventing distribution to minors, preventing revenue to criminal enterprises, and preventing diversion to states where marijuana remained illegal. The memo indicated that state-licensed marijuana businesses operating in compliance with robust state regulatory systems would not be federal enforcement priorities. The policy provided operational framework for the emerging legal cannabis industry.

Sessions Rescission (2018)

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, returning enforcement discretion to individual U.S. Attorneys. The Sessions Memo stated that marijuana remained illegal under federal law and that prosecutors should follow established principles of federal prosecution. The rescission created uncertainty across the industry but did not result in widespread federal enforcement actions. Most U.S. Attorneys continued deprioritizing state-compliant cannabis cases.

Biden DEA Rescheduling Initiative (2024-2025)

The Drug Enforcement Administration published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, proposing to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act. The proposal followed a recommendation from the Department of Health and Human Services based on a scientific review concluding marijuana has accepted medical use. The NPRM triggered a 60-day comment period that received over 43,000 submissions. Administrative Law Judge hearings began in November 2024 but remained incomplete when President Biden left office in January 2025.

Trump Administration Policy Shift (2026)

President Trump announced the medical marijuana reclassification policy on May 15, 2026, during a press conference at the White House. The policy bypassed the incomplete DEA rescheduling process by creating a new registration category under existing DEA authority. Attorney General Pam Bondi signed the implementing order, which took effect June 1, 2026. The policy applies only to medical marijuana programs, not recreational cannabis.

Key Players

Drug Enforcement Administration

The DEA administers the new registration system for state-licensed medical marijuana operators. Under the policy, medical dispensaries and cultivators must submit DEA Form 363-M, pay a $5,000 annual registration fee, and comply with federal tracking requirements using the DEA's Cannabis Tracking System. The agency issued interim final rules on May 20, 2026, establishing registration procedures. DEA Administrator Anne Milgram stated the agency would prioritize registration processing to meet the 180-day implementation deadline.

Department of Justice

The Department of Justice issued prosecutorial guidance on May 16, 2026, directing U.S. Attorneys not to prosecute registered medical marijuana operators in compliance with state law and federal registration requirements. The guidance does not create a safe harbor for recreational cannabis, unlicensed operators, or interstate trafficking. Deputy Attorney General Lisa Monaco emphasized that federal law enforcement would continue targeting illegal cannabis operations and diversion to minors.

Internal Revenue Service

The IRS has not issued guidance on whether registered medical marijuana operators remain subject to Section 280E of the Internal Revenue Code. Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Because the Trump policy does not reschedule marijuana, tax practitioners expect 280E to continue applying. The National Cannabis Industry Association estimated 280E costs the industry $1.8 billion annually in excess tax payments.

Multi-State Operators

Major cannabis companies responded positively to the reclassification. Curaleaf Holdings, which operates 145 dispensaries across 18 states, announced plans to register all medical locations by the August 1, 2026 deadline. CEO Matt Darin said the policy would enable the company to pursue traditional banking relationships and reduce cash-handling costs. Trulieve Cannabis, the largest medical marijuana operator in Florida with 185 dispensaries, projected the policy would reduce compliance costs by 15 percent annually.

State Regulatory Agencies

State cannabis control boards must coordinate with the DEA to verify licensee compliance. The California Department of Cannabis Control, which oversees 1,100 licensed medical cannabis businesses, established a dedicated DEA coordination unit. Director Nicole Elliott said the state would share track-and-trace data from the California Cannabis Track-and-Trace system with federal authorities. Similar coordination agreements were announced by regulatory agencies in Colorado, Massachusetts, Michigan, and Arizona.

Patient Advocacy Organizations

Americans for Safe Access, which represents medical marijuana patients, called the policy a significant step forward but noted it does not address access barriers including physician reluctance and insurance non-coverage. ASA Executive Director Debbie Churgai said the organization would continue advocating for full descheduling and FDA approval of cannabis medicines. The Epilepsy Foundation, which has supported medical marijuana access for seizure patients, welcomed the policy as reducing legal uncertainty for families using cannabis-based treatments.

Legal and Regulatory Framework

The Trump medical marijuana reclassification operates within existing Controlled Substances Act authority rather than amending the statute.

Controlled Substances Act Authority

The policy relies on 21 U.S.C. § 823, which grants the Attorney General authority to register manufacturers, distributors, and dispensers of controlled substances. The DEA historically used this authority to register pharmacies, hospitals, and physicians who handle Schedule II-V substances. The Trump policy extends registration to state-licensed medical marijuana operators handling a Schedule I substance, creating a novel regulatory category.

Registration Requirements

Registered medical marijuana operators must maintain detailed records of all cultivation, processing, and distribution activities. Records must be available for DEA inspection within 24 hours of request. Operators must report quarterly to the DEA using the Cannabis Tracking System, including data on plant counts, harvest weights, product inventory, and patient sales. The system integrates with state track-and-trace platforms including METRC, BioTrack, and Leaf Data Systems.

Limitations on Scope

The policy explicitly does not apply to recreational marijuana programs. Adult-use dispensaries in states including California, Colorado, Illinois, and New York remain subject to federal prosecution under 21 U.S.C. § 841. The policy also does not authorize interstate commerce in marijuana. Transporting cannabis across state lines remains a federal crime under 21 U.S.C. § 952, even between two medical marijuana states.

Preemption Analysis

The policy does not preempt state medical marijuana laws under principles of cooperative federalism. States retain authority to set possession limits, qualifying conditions, licensing requirements, and tax rates. However, state laws cannot conflict with federal registration requirements. If a state law prohibited sharing data with federal authorities, that provision would be preempted under the Supremacy Clause of Article VI.

Section 280E Tax Treatment

Internal Revenue Code Section 280E remains in effect because marijuana remains a Schedule I controlled substance. The section states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances." Cannabis businesses can deduct cost of goods sold but not operating expenses including rent, salaries, marketing, or utilities. Tax attorneys expect litigation over whether registered medical operators are still "trafficking" under 280E.

State-by-State Breakdown

The reclassification affects medical marijuana programs across 38 states, each with distinct regulatory frameworks and patient populations.

California

California operates dual medical and recreational programs under the Medicinal and Adult-Use Cannabis Regulation and Safety Act. The state has approximately 450,000 registered medical marijuana patients. Medical patients can possess up to eight ounces and cultivate up to six mature plants. The California Department of Cannabis Control began coordinating DEA registrations on May 20, 2026. Medical dispensaries pay a 15 percent excise tax, lower than the combined taxes on recreational sales.

Florida

Florida has the second-largest medical marijuana program with over 850,000 registered patients. The state authorizes 22 licensed Medical Marijuana Treatment Centers, each operating multiple dispensaries. Florida law requires vertical integration, meaning licensees must cultivate, process, and dispense their own products. Patients can possess up to a 70-day supply as determined by their physician. The Florida Department of Health Office of Medical Marijuana Use announced it would facilitate DEA registration for all licensed operators.

Oklahoma

Oklahoma operates the most permissive medical marijuana program with over 380,000 patients and 2,400 licensed dispensaries. The state has no qualifying condition list; any physician can recommend cannabis for any condition. Patients can possess up to three ounces in public and eight ounces at home. The Oklahoma Medical Marijuana Authority said the state's decentralized licensing system would require individual dispensaries to complete DEA registration rather than batch processing.

Pennsylvania

Pennsylvania has 450,000 registered medical marijuana patients and restricts the program to 23 qualifying conditions including cancer, epilepsy, and PTSD. The state prohibits smokable flower, limiting patients to vaporization, tinctures, and edibles. Pennsylvania licenses 50 grower-processors and 150 dispensaries. The Department of Health announced it would verify compliance with state law before endorsing DEA registration applications.

Arizona

Arizona voters approved medical marijuana in 2010 and recreational cannabis in 2020. The state has 130,000 active medical marijuana cardholders who can possess up to 2.5 ounces. Medical patients receive tax exemptions and higher possession limits than recreational users. The Arizona Department of Health Services said it would prioritize medical-only dispensaries for DEA registration coordination.

New York

New York transitioned from a restrictive medical program to adult-use legalization in 2021. The state has 180,000 registered medical marijuana patients who can possess up to a 60-day supply. Medical dispensaries operate separately from adult-use retailers. The New York Office of Cannabis Management announced it would require medical dispensaries to obtain DEA registration by September 1, 2026, as a condition of state license renewal.

Ohio

Ohio launched its medical marijuana program in 2019 and approved recreational legalization in 2023. The state has 250,000 registered patients and 130 licensed dispensaries. Medical patients can purchase up to a 90-day supply based on physician recommendation. The Ohio Division of Cannabis Control said it would integrate DEA registration status into the state's licensing database.

Market and Business Implications

The reclassification creates immediate operational benefits for medical marijuana operators while leaving fundamental economic challenges unresolved.

Banking Access

The policy's most significant business impact is expanded banking access. Previously, financial institutions serving cannabis businesses risked prosecution under 18 U.S.C. § 1956 for money laundering and 18 U.S.C. § 1957 for monetary transactions in property derived from specified unlawful activity. The American Bankers Association issued guidance on May 18, 2026, stating that banks could serve DEA-registered medical marijuana operators without violating the Bank Secrecy Act. JPMorgan Chase and Bank of America announced they would begin accepting medical cannabis accounts in June 2026.

Expanded banking access reduces operational costs significantly. Cannabis businesses operating on an all-cash basis spend an estimated 10-15 percent of revenue on cash handling, armored transport, and security. Curaleaf CFO Neil Davidson projected the company would save $22 million annually by transitioning to electronic payments. Banking access also enables credit card processing, which industry analysts expect to increase average transaction sizes by 15-20 percent.

Capital Markets

The policy does not resolve barriers to U.S. capital markets. Cannabis companies remain prohibited from listing on the New York Stock Exchange or Nasdaq because those exchanges require compliance with federal law. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries trade on the Canadian Securities Exchange. Investment banks including Cowen and Canaccord Genuity said they would expand coverage of medical-focused cannabis companies following the reclassification.

Institutional investment remains limited. Many pension funds, endowments, and mutual funds have policies prohibiting investment in federally illegal activities. The policy's limitation to medical marijuana means institutional investors cannot access the larger recreational market, which generated $28 billion in sales in 2025 compared to $15 billion for medical.

Section 280E Tax Burden

The continuation of Section 280E represents the policy's most significant economic limitation. Cannabis businesses pay effective tax rates of 70-90 percent because they cannot deduct rent, salaries, utilities, or other operating expenses. A typical medical dispensary with $5 million in revenue, $3 million in cost of goods sold, and $1.5 million in operating expenses would owe federal tax on $2 million rather than $500,000 in net income.

The National Cannabis Industry Association estimated 280E costs medical marijuana operators $1.1 billion annually. Trulieve CEO Kim Rivers said the company paid $180 million in excess federal taxes in 2025 due to 280E. Industry advocates are lobbying Congress to amend Section 280E to exempt DEA-registered medical marijuana operators, but no legislation has been introduced as of May 2026.

Interstate Commerce Prohibition

The policy's prohibition on interstate commerce prevents economies of scale and market efficiency. Large cultivators in low-cost production states like Oklahoma cannot ship to high-price markets like New York or New Jersey. Each state requires in-state cultivation, processing, and testing, duplicating infrastructure and increasing costs. Wholesale marijuana prices range from $800 per pound in Oklahoma to $3,200 per pound in New Jersey for similar quality flower.

Industry economists estimate interstate commerce would reduce consumer prices by 30-40 percent and consolidate production in optimal climates. However, state governments oppose interstate commerce because it would eliminate local cultivation jobs and reduce tax revenue from in-state production.

Medical vs. Recreational Market Dynamics

The policy creates a two-tier system favoring medical operators. In states with both medical and recreational programs, medical dispensaries gain competitive advantages including federal legal recognition, banking access, and potentially lower regulatory costs. However, the medical market has grown more slowly than recreational. Medical marijuana sales increased 8 percent in 2025 while recreational sales grew 23 percent, according to BDSA Analytics.

Some operators may shift focus to medical programs. Verano Holdings CEO George Archos said the company would prioritize medical dispensary expansion in states like Florida, Pennsylvania, and Ohio where medical programs remain larger than recreational. Other operators including Curaleaf maintain that recreational cannabis represents the larger long-term opportunity despite federal legal uncertainty.

What Experts Say

Legal scholars, industry analysts, and policy experts offered varied assessments of the reclassification's significance and limitations.

Robert Mikos, a law professor at Vanderbilt University and cannabis federalism expert, described the policy as "an incremental step that reduces federal-state conflict without resolving fundamental legal questions." According to Mikos, the policy does not change marijuana's Schedule I status, does not create a constitutional right to medical marijuana, and could be reversed by a future administration. He noted the policy relies on prosecutorial discretion rather than statutory change, making it vulnerable to political shifts.

Hilary Bricken, a cannabis attorney at Harris Bricken, said the policy provides "meaningful operational relief for medical operators while leaving the industry's core legal problems intact." Bricken emphasized that Section 280E, interstate commerce restrictions, and FDA regulatory authority remain unchanged. She advised clients to pursue DEA registration but continue advocating for comprehensive federal reform including descheduling and interstate commerce authorization.

Aaron Smith, co-founder of the National Cannabis Industry Association, called the policy "a welcome development that validates state medical marijuana programs after 30 years of federal-state conflict." Smith said the policy would reduce banking barriers and enable medical operators to access basic financial services. However, he emphasized that full legalization remains necessary to address 280E, enable interstate commerce, and provide certainty for recreational programs serving 100 million Americans in legal states.

According to Cowen analyst Vivien Azer, the reclassification creates a "medical premium" for operators with significant medical market share. Azer upgraded Trulieve and Curaleaf to outperform ratings based on their medical dispensary footprints. She projected the policy would expand medical market growth from 8 percent annually to 12 percent as physicians become more comfortable recommending cannabis without federal prosecution risk.

Sam Kamin, a professor at the University of Denver Sturm College of Law, noted the policy raises questions about equal protection and federalism. According to Kamin, creating different federal treatment for medical versus recreational marijuana may be difficult to justify given that both involve the same Schedule I substance. He predicted legal challenges from recreational operators arguing the policy creates arbitrary distinctions without rational basis.

Kevin Sabet, president of Smart Approaches to Marijuana and a legalization opponent, criticized the policy as "backdoor legalization that undermines the Controlled Substances Act." Sabet argued the policy contradicts marijuana's Schedule I classification and sets a precedent for state nullification of federal drug law. He called for maintaining federal prohibition while expanding research into FDA-approved cannabis-derived medications.

What's Next

The reclassification's implementation and durability depend on regulatory execution, legal challenges, and potential congressional action.

Implementation Timeline

The DEA opened the registration portal on June 1, 2026, with a 180-day window for existing state-licensed medical marijuana operators to submit applications. The agency projected processing 8,000-10,000 registrations by the November 28, 2026 deadline. Operators who miss the deadline face potential federal prosecution. The DEA hired 150 additional compliance officers to conduct inspections and verify state license validity.

Legal Challenges

Multiple legal challenges are expected. Smart Approaches to Marijuana announced plans to file suit in federal district court arguing the policy exceeds the Attorney General's authority under the Controlled Substances Act. The organization will argue that 21 U.S.C. § 823 does not authorize registration of businesses trafficking in Schedule I substances for non-research purposes.

Recreational cannabis operators in California and Colorado are considering equal protection challenges. Their argument would contend that medical and recreational marijuana are chemically identical and that creating different federal treatment lacks rational basis. However, courts have historically granted substantial deference to drug classification decisions.

Congressional Action

Senator Cory Booker and Representative Nancy Mace introduced the States Reform Act on May 20, 2026, which would deschedule marijuana entirely and regulate it similarly to alcohol. The bill has 38 Senate cosponsors and 180 House cosponsors but faces opposition from Senate Judiciary Committee Chairman Tom Cotton. Senate Majority Leader John Thune has not committed to bringing the bill to a floor vote.

The SAFER Banking Act, which would protect financial institutions serving state-legal cannabis businesses, passed the House 258-162 on April 15, 2026, but stalled in the Senate. Senator Sherrod Brown said he would continue pushing for Senate consideration, but opponents including Senator John Kennedy argued the bill would facilitate recreational marijuana expansion.

State Responses

Several states are considering legislation to align state law with federal registration requirements. The Florida Legislature introduced HB 1847 on May 22, 2026, which would require Medical Marijuana Treatment Centers to maintain DEA registration as a condition of state licensure. Similar bills are under consideration in Pennsylvania, Ohio, and Arizona.

Some states with recreational programs are exploring medical program expansion to take advantage of federal recognition. New York Governor Kathy Hochul announced a proposal to reduce medical marijuana card fees from $50 to $10 and expand qualifying conditions. The goal is to shift consumers from recreational to medical purchases to benefit from federal legal protection.

Industry Consolidation

Investment bankers project the policy will accelerate medical cannabis industry consolidation. Larger operators with access to capital can acquire smaller medical dispensaries to build scale and market share. Viridian Capital Advisors tracked $420 million in medical cannabis M&A transactions in the two weeks following the reclassification announcement, compared to $180 million in the prior month.

Curaleaf announced on May 25, 2026, that it was pursuing acquisitions of medical dispensaries in Florida, Pennsylvania, and Ohio. CEO Matt Darin said the company would prioritize medical assets given the improved federal legal status. Trulieve similarly announced a $75 million acquisition of a Pennsylvania medical marijuana operator with 12 dispensaries.

International Implications

The policy may influence international cannabis policy debates. Germany launched a limited medical marijuana program in 2024 and is considering broader legalization. Canadian cannabis companies including Canopy Growth and Tilray, which have struggled with domestic market saturation, are exploring partnerships with U.S. medical operators. However, the policy does not change import-export restrictions under 21 U.S.C. § 952, preventing cross-border commerce.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.deadiversion.usdoj.gov/21cfr/21usc/
• DEA Interim Final Rule on Medical Marijuana Registration, 91 Fed. Reg. 28,450 (May 20, 2026) — https://www.federalregister.gov
• Department of Justice Prosecutorial Guidance on State-Licensed Medical Marijuana (May 16, 2026) — https://www.justice.gov
• Gonzales v. Raich, 545 U.S. 1 (2005) — https://supreme.justia.com/cases/federal/us/545/1/
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — https://www.law.cornell.edu/uscode/text/26/280E
• National Conference of State Legislatures, State Medical Marijuana Laws — https://www.ncsl.org/health/state-medical-cannabis-laws
• BDSA Analytics, U.S. Cannabis Market Report 2025 — https://www.bdsa.com
• Americans for Safe Access, Medical Marijuana Access in America — https://www.safeaccessnow.org
• Congressional Research Service, Marijuana: Medical and Retail — Selected Legal Issues (R44782) — https://crsreports.congress.gov
• California Department of Cannabis Control, Medical Cannabis Regulation — https://cannabis.ca.gov

Update — May 17, 2026: Administration Clarifies Scope of Medical Marijuana Reclassification

The Trump administration released guidance clarifying that its reclassification policy applies exclusively to state-licensed medical marijuana programs, not recreational cannabis operations. According to the Department of Justice memorandum issued May 16, 2026, the new Schedule III designation covers only cannabis products dispensed through state-approved medical programs with physician recommendations. Recreational dispensaries in states with adult-use laws remain subject to existing federal enforcement priorities under the Controlled Substances Act.

The guidance specified that medical marijuana businesses must maintain state licensure in good standing to benefit from reduced federal banking restrictions and tax treatment changes. Operators who lose state licenses or operate outside medical program parameters will revert to Schedule I enforcement status, the memorandum said. Financial institutions can now service state-licensed medical dispensaries without filing Suspicious Activity Reports for standard banking transactions, effective June 1, 2026.

The clarification addressed confusion among 38 states with medical marijuana programs regarding which operations qualify for the new classification. State regulators in California, Colorado, and Washington—which operate dual medical and recreational markets—requested specific guidance on program segregation requirements. The DOJ confirmed that dispensaries serving both patient populations must maintain separate inventory tracking and point-of-sale systems to distinguish medical from recreational sales.

Industry analysts noted the policy creates a two-tier federal compliance framework that may incentivize some recreational operators to pursue medical licenses in states allowing dual licensing. Tax implications remain significant: medical cannabis businesses can now deduct ordinary business expenses under IRC Section 280E modifications, while recreational operators continue facing the prohibition. This matters because the effective tax rate differential between medical and recreational operations now exceeds 40 percentage points in most jurisdictions, according to cannabis accounting firms.

The guidance did not address pending legislation to fully deschedule cannabis or resolve conflicts between state recreational laws and federal prohibition. Twenty-four states with adult-use programs saw no change in federal enforcement posture for recreational sales, leaving approximately 12,000 recreational dispensaries in the same legal gray area that existed before reclassification.